Thank you for subscribing!
Finfeed Feb 28, 2022
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.
Next Investors Feb 28, 2022
Finfeed Feb 01, 2022
Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.
Finfeed Oct 15, 2021
Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.
Get expert stock analysis direct in your inbox
Next Investors Sep 27, 2021
On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.
Finfeed Sep 24, 2021
The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.
Finfeed Archived Apr 22, 2021
Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.
Finfeed Archived Mar 18, 2021
Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.
Finfeed Archived Mar 12, 2021
The Australian market together with South Africa continue to be the best performing stocks markets in the world and have been for over 100 years.
Finfeed Archived Feb 19, 2021
In times of crisis, it seems that governments around the world are more than happy to continue to dish out ever increasing stimulus packages to solve the problem but are they just delaying the inevitable or are they spending our grandchildren’s future?
Finfeed Archived Dec 17, 2020
Achiko (SWX: ACHI), listed on the Switzerland Stock Exchange during the year, is transforming into a health technology company with the rapid development of Teman Sehat, an open source software product that provides an alternative way to manage Covid-19 testing, and ‘Gumnuts’, a potential rapid and low-cost virus detection technology.
Finfeed Archived Dec 08, 2020
Stocks were impacted last night as COVID-19 infections swept through the US again, putting the fear of further restrictions into investors.
Finfeed Archived Oct 30, 2020
Despite retailers doing it tough throughout the COVID-19 global pandemic, there are certain suppliers that have managed to not only remain operational, but also thrive in a trying environment. Alexium International Group (ASX: AJX) is one.
Finfeed Archived Sep 04, 2020
How could a virus press pause on global sustainability goals and instead make plastic fantastic again?
Finfeed Archived Aug 31, 2020
To put things in perspective, the Dow Jones last traded around this level of February 21, a day on which the US recorded one new COVID-19 case.
Finfeed Archived Aug 28, 2020
Airbnb hasn’t been immune to the hospitality downturn, so it does seem a strange time to IPO. It would certainly rub the noses of the 25% of Airbnb staff that was laid off in May.
Finfeed Archived Aug 21, 2020
The S&P 500 regained all of the losses it suffered in March, when the pandemic hit. It is up 16.8% over the past 12 months. The stocks that make up the S&P 500 are mostly those which are trying to change the world in light of COVID-19.
Finfeed Archived Aug 14, 2020
Right now, it’s important to understand your level of exposure to Australian equities, particularly if the stock market crashes again, as some experts are predicting.
Join Our Mailing List
